SCHEMBL38539

SCHEMBL38539

COc1cn[c]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL992408 0.76 — —
SCHEMBL972789 0.76 TSHR (0.36) —
SCHEMBL11779433 0.73 GABRP (0.35) —
SCHEMBL3138241 0.72 SIRT6 (0.56) —
SCHEMBL991144 0.71 — —
SCHEMBL17540979 0.70 SLC6A3 (0.38) —
SCHEMBL990506 0.70 — —
SCHEMBL15142636 0.70 — —
SCHEMBL11902638 0.69 ADAM17 (0.31) —
SCHEMBL446963 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4399206-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES Redona Therapeutics, Inc. (US) 2024-07-17 — — EP claimed
CN-118201911-A Compounds and their use as GPR183 inhibitors 南京艾美斐生物医药科技有限公司 2024-06-14 — — CN claimed
CN-118201914-A 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors 雷多纳治疗公司 2024-06-14 — — CN claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US claimed
CN-113004278-B Bicyclic heterocycles as FGFR inhibitors 因赛特控股公司 2023-07-21 — — CN claimed
WO-2023039089-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES TWENTYEIGHT-SEVEN, INC. (US) 2023-03-16 — — WO claimed
CN-113004278-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2021-06-22 — — CN claimed
EP-3180330-B1 2,2,2-TRIFLUOROETHYL-THIADIAZINES HOFFMANN LA ROCHE (CH) 2021-03-03 — — EP claimed
CN-107438607-B Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2021-02-05 — — CN claimed
CN-106459006-B 2,2, 2-trifluoroethyl-thiadiazines 豪夫迈·罗氏有限公司 2020-02-11 — — CN claimed
WO-2010103437-A1 BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS PFIZER INC. (US) 2010-09-16 — — WO claimed
US-20100234285-A1 Benzofuranyl Derivatives PFIZER INC 2010-09-16 — — US claimed
US-20090253906-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2009-10-08 — — US claimed
US-7541357-B2 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin AMR TECHNOLOGY, INC. (US) 2009-06-02 — — US claimed
US-20090048443-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2009-02-19 — — US claimed
WO-2009015193-A1 ANTIBACTERIAL SULFONE AND SULFOXIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 — — WO claimed
EP-1778639-A2 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2007-05-02 — — EP claimed
US-20060052378-A1 Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride CURIA GLOBAL, INC. 2006-03-09 — — US claimed
WO-2006020049-A2 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2006-02-23 — — WO claimed
US-3951966-A XANTHINE OXIDASE INHIBITORS MERCK & CO., INC. (US) 1976-04-20 — — US claimed
Send feedback